Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Matthew Adler

Physician Assistant, Medical Brighton, MI Physician Assistant

NPI 1033293659 CMS profile 10899794

2300 Genoa Business Park Dr, Suite 220, Brighton, MI 48114

Open in the dashboard

General payments

$21,784

1,458 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Matthew Adler of Brighton, MI is reported in the CMS Open Payments database as having received $21,784 across 1,458 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,191 358
2024 General $4,796 317
2023 General $4,231 285
2022 General $4,628 264
2021 General $2,938 234

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Matthew Adler
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Matthew Adler were reported at $5,191. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Matthew Adler Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $2,938 $156 $41–$563 $132
2022 $4,628 $185 $55–$649 $149
2023 $4,231 $199 $58–$717 $160
2024 $4,796 $206 $62–$740 $164
2025 $5,191 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Sun Pharmaceutical Industries Inc. $4,315 261 payments
  2. Janssen Biotech, Inc. $3,513 199 payments
  3. AbbVie, Inc. $2,324 175 payments
  4. Novartis Pharmaceuticals Corporation $1,532 115 payments
  5. Incyte Corporation $1,351 91 payments
  6. Galderma Laboratories, L.P. $1,220 136 payments
  7. E.R. Squibb & Sons, L.L.C. $1,028 124 payments
  8. Genzyme Corporation $889 39 payments
  9. UCB, Inc. $864 33 payments
  10. Regeneron Healthcare Solutions, Inc. $864 36 payments
  11. Other $3,884 249 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $20,095 1,442 payments
  2. Education $1,011 13 payments
  3. Consulting Fee $650 1 payment
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $29 2 payments
Products named General payments · program years 2021–2025
  1. ILUMYA $3,424 208 payments
  2. TREMFYA $3,124 165 payments
  3. OPZELURA $1,344 90 payments
  4. DUPIXENT $1,270 53 payments
  5. SOTYKTU $968 119 payments
  6. SKYRIZI $908 66 payments
  7. RINVOQ $905 80 payments
  8. COSENTYX $834 62 payments
  9. AKLIEF $624 70 payments
  10. Bimzelx $568 18 payments
  11. Other $11,037 795 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

700

Median for Physician Assistant: 241

Drug cost

$274,924

Median for Physician Assistant: $4,110

Branded share of claims

10.4%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Cosentyx Sensoready (2 Pens) Secukinumab Brand 25 $185,059
Otezla Apremilast Brand 16 $74,804
Clobetasol Propionate Generic 126 $3,606
Tacrolimus Generic 25 $2,355
Metronidazole Generic 32 $1,641
Azelaic Acid Generic 11 $1,457
Triamcinolone Acetonide Generic 123 $1,163
Ciclopirox Generic 26 $849
Ketoconazole Generic 59 $784
Econazole Nitrate Generic 39 $695

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 32 billing codes

Paid by Medicare

$81,013

Medicare's payments for the services billed

Medicare patients

471

Average age 75

Services billed

2,873

188 women, 283 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 66%
Arthritis 43%
Ischemic heart disease 25%
Diabetes 24%
Chronic kidney disease 17%
Atrial fibrillation 16%
Cancer 16%
Depression 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 32 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ILUMYA
$653 — —
OPZELURA
$452 — —
DUPIXENT
$445 — —
TREMFYA
$421 — —
COSENTYX
$337 25 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 32 with Patron

Records

1,458 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record